Pelthos Therapeutics Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 12/100
What the filing says
Filing discloses the standard Performance Stock Unit (PSU) agreement template under Pelthos Therapeutics' 2023 Equity Incentive Plan. No specific grant amounts, recipient names, performance criteria, vesting schedules, or dollar values are stated in this document—it is a boilerplate agreement form. Actual grant details would appear separately in individual customizing information sheets not included in this exhibit. SOX certifications by CEO Scott Plesha and CFO John M. Gay dated August 13, 2026 confirm the Q2 2026 10-Q filing.
Why this rating
Routine disclosure of equity plan agreement template; no material business transaction, financial impact, or strategic change. Standard governance filing.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.